Company Overview and News

 
Collaborate Corporation achieves record rental transaction value in December quarter

2018-01-15 proactiveinvestors.com.au
Collaborate Corporation Ltd’s (ASX:CL8) strong December quarter should assist in funding its expansion in the collaborative consumption industry, particularly in launching its caravan rental platform.

 
Collaborate Corporation launches new co-branded car rental website in Victoria

2017-09-25 proactiveinvestors.com.au
Collaborate Corporation Ltd’s (ASX:CL8) DriveMyCar business unit has launched the RACV DriveMyCar website, its first product in collaboration with RACV in Victoria.

 
Collaborate Corporation expands its partnership with Subaru Australia

2017-06-26 proactiveinvestors.com.au
Collaborate Corporation (ASX:CL8) will add 105 new 2018 model Subaru XV vehicles for rental through its DriveMyCar platform in September 2017.

 
Collaborate Corporation shares rise on securing strategic investment

2017-04-27 proactiveinvestors.com.au
Collaborate Corporation’s (ASX:CL8) shares traded higher yesterday after securing a strategic investment of $1 million from the Royal Automobile Club of Victoria (RACV).

 
Collaborate Corporation attracts funding

2017-04-24 proactiveinvestors.com.au
Collaborate Corporation (ASX:CL8) has been granted a trading halt by the ASX, pending details of a strategic investment.

 
Collaborate Corporation shares gain on record car rental growth

2017-03-20 proactiveinvestors.com.au
Collaborate Corporation’s (ASX:CL8) DriveMyCar business unit is on track to deliver another quarter of strong growth, with a number of sales records broken before the end of the March 2017 quarter.

 
Collaborate Corporation adds 101 Subaru Imprezas to its fleet

2017-02-14 proactiveinvestors.com.au
Collaborate Corporation (ASX:CL8) is expanding the fleet size of its DriveMyCar rental service with the addition of 101 Subaru Impreza 2017 model vehicles.

 
Collaborate Corporation Ltd launches rental service for Uber drivers

2016-09-05 proactiveinvestors.com.au
Collaborate Corporation Ltd’s (ASX:CL8) shares were last trading about 17% higher for the day, after launching a rental car offering for UberX driver-partners in Brisbane and Melbourne. The company's move into Brisbane was made possible by the state of Queensland making ride-sharing legal from today. Victoria legalised ride sharing last month. Collaborate’s DriveMyCar ride-share rental offering for UberX driver-partners was launched in July 2016 in Sydney and the initial uptake has been very strong.

 
Collaborate Corporation Ltd to offer ride share cars on Uber platform

2016-06-24 proactiveinvestors.com.au
Collaborate Corporation Ltd (ASX:CL8) has opened a new market for its vehicle rental service with an agreement to advertise these to UberX ride share driver/partners through Uber Marketplace. Car owners are using the Collaborate platform to generate income from under utilised vehicles. While UberX is a portal operated by Uber which advertises vehicle solutions to prospective uberX driver-partners. Collaborate’s DriveMyCar business unit will start advertising ride share vehicle rental services to uberX ride share driver-partners on the Uber Marketplace.

 
Appendix 3B

2016-05-11 asx.com.au

 
 
Collaborate Corporation Ltd to reveal fundraiser

2016-05-02 proactiveinvestors.com.au
Collaborate Corporation Ltd (ASX:CL8) is heading to market with a capital raising, and the ASX has granted the company a trading halt to prepare. The halt will remain in place until the opening of trade on Wednesday 4th May 2016, or earlier if an announcement is made to the market.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

16h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

16h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...